2022

1. Editorial: Advances in non-alcoholic fatty liver disease therapeutics: Pathogenic mechanisms and targets

   Frontiers in Pharmacology

2. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

   Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734